
Superpower peptides available for pre-order. Get first access.

Peptide science
How do GIP-based drugs work?
GIP-based drugs either activate or block the GIP receptor. See how tirzepatide, VK2735, retatrutide, and MariTide differ, and why both lower weight.
Quick answer
GIP-based drugs either activate or block the GIP receptor while also activating the GLP-1 receptor. Tirzepatide, the only FDA-approved one, activates it. Investigational VK2735 (Phase 3 VANQUISH one trial, planned enrollment of about 4,500) does too, while MariTide (Phase 3 MARITIME-1 trial, 3,853 adults) blocks it. Both approaches lower weight in studies, yet researchers have not established why blocking GIP works.
- Published
- November 9, 2026
- Last updated
- November 9, 2026
What GIP-based drugs do at the GIP receptor
Glucose-dependent insulinotropic polypeptide drugs, or GIP-based drugs, either activate or block the GIP receptor while also activating the GLP-1 receptor. Each approach grew from its own human, genetic, and animal evidence. In clinical studies, both add weight loss to GLP-1 activation1.
| Drug | Action at the GIP receptor | Other receptors activated | US status |
| Tirzepatide (Mounjaro, Zepbound) | Activates | GLP-1 | FDA-approved for type 2 diabetes and chronic weight management2 |
| VK2735 | Activates3 | GLP-1 | Investigational, in the Phase 3 VANQUISH 1 trial4 |
| Retatrutide | Activates | GLP-1 and glucagon5 | Investigational, not FDA-approved |
| MariTide (maridebart cafraglutide) | Blocks6 | GLP-1 | Investigational, in the Phase 3 MARITIME-1 trial7 |
Tirzepatide, the one FDA-approved drug of the four, is the natural place to start.
What GIP does in tirzepatide (Mounjaro)
Tirzepatide (Mounjaro) is a single molecule that activates both the GIP and GLP-1 receptors8. Dual agonist and co-agonist are two names for that two-receptor design. Tirzepatide was built to test whether GIP's metabolic effects add to GLP-1 activation. How much of tirzepatide's effect comes from the GIP side is still debated.
GIP reduces food intake and body weight in rodents, but those effects had not been shown in humans9 as of 2022. Since then, a small Phase 1 trial of a long-acting GIP-only agonist reported dose-dependent weight loss10. Against semaglutide, a GLP-1-only drug, tirzepatide lowered HbA1c more over 40 weeks11 in people with type 2 diabetes. A head-to-head result like that still cannot separate what the GIP side contributed.
One proposed role for the GIP side is easing GLP-1-driven nausea. In rodents and musk shrews, GIP receptor signaling eased GLP-1-driven illness behaviors and vomiting12, while food intake stayed reduced. In people, that role remains a hypothesis.
Tirzepatide makes the case for activating GIP, yet blocking the same receptor also lowers weight.
GIP agonists vs antagonists: why both lower weight
Paired with GLP-1 receptor activation, GIP agonists and GIP antagonists have produced similar effects on weight loss13 in clinical studies. Researchers have not settled why.
A GIP receptor agonist activates the receptor the way the natural hormone does. A GIP receptor antagonist binds the receptor and blocks it. Tirzepatide is one molecule that activates both receptors, while MariTide is a GIP receptor-blocking antibody joined to two GLP-1-activating peptides6.
| Evidence | GIP receptor agonist approach | GIP receptor antagonist approach |
| Proposed reason it adds to GLP-1 | Review argues brain GIP receptor activity curbs appetite and fat-tissue activity guards against fat in organs14 | Mice lacking the GIP receptor, body-wide or in the brain, resisted diet-induced obesity15 |
| Founding evidence | Balanced GLP-1/GIP co-agonist lowered glucose more than GLP-1-only drugs16 in rodents, monkeys, and humans; added fat loss in obese rodents | GIP receptor-blocking antibody joined to GLP-1 peptides cut weight in obese mice and monkeys6 |
| First human weight results | Tirzepatide, the first single-molecule dual agonist in clinical use, brought large glucose and weight reductions17 | Early-phase MariTide trial in people with obesity reported marked weight loss18 |
The mechanisms behind this apparent paradox15 remain unknown. One proposal is that a long-acting agonist comes to act like a blocker over time.
How GIP receptor desensitization may explain the paradox
A long-acting GIP agonist may end up working like an antagonist, because constant activation desensitizes GIP receptors in fat cells19. The supporting evidence comes from cultured fat cells and mice, so desensitization remains a hypothesis in people.
People with obesity tend to have normal or raised GIP levels20, though GIP's insulin-releasing effect is blunted. Whether the benefits of blocking GIP seen in preclinical models extend to humans has yet to be determined21. Human genetics and head-to-head animal studies probe the two directions more directly.
Evidence on GIP from human genetics and animal studies
Human genetic data and mouse experiments both support the GIP receptor as a weight target. Neither settles which direction works better in people, and further human studies are needed22. The evidence spans four kinds of research.
- Human genetics: people with GIP receptor variants that weaken two signaling routes show lower adiposity-related traits23
- Mouse comparison: an agonist and an antagonist each cut weight in obese male mice22; the agonist alone improved glucose tolerance
- Mouse mechanisms: in male mice, the agonist acted through brain neurons, while the antagonist's effect needed GLP-1 signaling24
- Healthy volunteers: a selective GIP receptor antagonist was infused into 10 healthy young men25 to study bone metabolism
Several mouse findings point to the brain, where GIP receptors appear in regions that control eating.
GIP receptors in the brain may regulate food intake
In mouse studies, GIP receptors appear on neurons in the hypothalamus and hindbrain26 that help control eating. Switching on either group of neurons reduced food intake, each through a different mechanism.
In preclinical models, brain GIP receptor signaling appears essential27 for GIP's effect on appetite. Still, where and how GIP acts in the brain28 remains uncertain. Most of that brain evidence comes from rodents, while human evidence on GIP-based drugs comes from clinical trials.
Where glucose-dependent insulinotropic polypeptide drugs stand today
Tirzepatide is the only GIP-based drug with FDA approval2, while VK2735 and MariTide remain in Phase 3 trials.
MariTide's Phase 3 MARITIME-1 trial enrolled 3,853 adults7 with obesity or overweight and has not posted results. VK2735's 78-week Phase 3 VANQUISH one trial4 is also active, with no results posted.
Every drug in the class also carries the core action of GLP-1 receptor agonists. Direct agonist-versus-antagonist comparisons have so far come from mouse studies. These two Phase 3 trials instead compare each drug with placebo, measuring the percent change in body weight.
Where can I learn about peptides?
Headlines about GIP-based drugs often blur the line between an approved medicine and a Phase 3 candidate. Superpower’s peptide library keeps that distinction clear. Its content comes from a team of health journalists and licensed clinicians who write and fact-check each page.
Reading about the science behind peptides helps explain how one receptor can be switched on by one drug and blocked by another.
IMPORTANT SAFETY INFORMATION
Tirzepatide is a prescription medication. Its FDA-approved labeling (Mounjaro, Zepbound) carries a boxed warning for risk of thyroid C-cell tumors; tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide is not recommended during pregnancy. Serious adverse events reported include pancreatitis, gallbladder disease, acute kidney injury, and severe gastrointestinal reactions. Common adverse events include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and injection-site reactions.
Compounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, effectiveness, or quality. A patient-specific prescription is required. Tirzepatide Rx is not available in all 50 states.
VK2735, retatrutide, and MariTide (maridebart cafraglutide) are investigational drugs that are not FDA-approved for any use. They are not available by prescription, and access is limited to clinical trial enrollment. Nausea, vomiting, and other gastrointestinal effects were common in their published trials.
This article is for general information and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any prescription medication.
Full FDA-approved prescribing information for tirzepatide is available on DailyMed29.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health facilitates access to compounded tirzepatide through licensed healthcare providers and compounding pharmacy partners. Compounded tirzepatide is NOT equivalent to the branded products (Mounjaro or Zepbound). Superpower does not sell, prescribe, or facilitate access to any branded version of tirzepatide, or to VK2735, retatrutide, or MariTide. Compounded tirzepatide is a prescription medication available only by prescription. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.